# EV426999744US 12-07-06

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

Hoder the Pa	menwork Reduction Act of 1995	no persons	U.S. s are required to respond to a co	Patent and Tr	rademark (	Office; U	S. DEPARTMENT OF COMMERO
XPE	DELINOTIC TORGETTION OF THE PROPERTY OF THE PR		Application Number	09/7/19,410			
RANSMITTAL			Filing Date	12-Dec-200	12-Dec-2000		
0 5 2006 y FORM		i i	First Named Inventor	GOKE, Bui	GOKE, Burkhard, et al.		
Æ/			Art Unit	1654			
RADEN Le used for	all correspondence after initial	filina)	Examiner Name	монаме	D, Abdel A	•	
		162	Attorney Docket Number	0206-UTL-	-9		
Total Number of	f Pages in This Submission			_ <u></u>			
		ENCL	OSURES (Check al	I that apply	)		
Fee Tran	smittal Form	, []	Drawing(s)			After A	llowance Communication to To
	ee Attached		icensing-related Papers				l Communication to Board eals and Interferences
Amendm	ent/Reply	 	Petition			Appea (Appea	I Communication to TC I Notice, Brief, Reply Brief)
	fter Final		Petition to Convert to a Provisional Application Power of Attorney, Revocation			Proprie	etary Information
		F				Status	l etter
	ffidavits/declaration(s)		Change of Correspondence	Address		Other	Enclosure(s) (please Identify
Extensio	n of Time Request	<u> </u>	Terminal Disclaimer   ✓		Cited	below)	
Express	Abandonment Request	<u> </u> F	Request for Refund		Cited	Reiere	nces (158 pages); Post Card
<b>✓</b> Informati	on Disclosure Statement		CD, Number of CD(s)				
		Г	Landscape Table on C	D			
Certified	Copy of Priority	Remark			<u> </u>		
Docume	nt(s)						
	Missing Parts/ ete Application						
F	Reply to Missing Parts						
u	nder 37 CFR 1.52 or 1.53						
	SIGNA	TURE O	F APPLICANT, ATTO	DRNEY, C	OR AGE	-NI	
Firm Name	Amylin Pharmaceuticals,	Inc.					
Signature	2	But					
Printed name	BUTLER, Vames E.				-		
Date	5-Dec-2006			Reg. No.	40,931		
	C	ERTIFIC	CATE OF TRANSMISS	SION/MAI	ILING		
I hereby certify the sufficient postage the date shown I	e as first class mail in an er	peing facsing velope add	mile transmitted to the USP dressed to: Commissioner fo	TO or depos or Patents, F	sited with P.O. Box	the Un 1450, /	ited States Postal Service wit Alexandria, VA 22313-1450 o
Signature	JOHN.	2,50	show pn			- <u></u> ,	
Typed or printed	name Kelly B. Solomo	<u> </u>				Date	6-Dec-2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

GOKE, et al

Art Unit:

1654

Appln. No.: 09/719,410

Examiner:

Mohamed, A.

Filed:

12-Dec-2000

Atty. Docket:

0206-UTL-9

For:

GLUCAGON-LIKE PEPTIDE-1 IMPROVES

BETA-CELL RESPONSE TO GLUCOSE IN

SUBJECTS WITH IMPARIED GLUCOSE

TOLERANCE (AMENDED)

Confirm. No.: 8826

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicant submits copies of the references listed on the attached PTO Form PTO/SB/08A for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein. In accordance with 37 C.F.R. 1.98, copies of cited U.S. Patents and U.S. Patent Application Publications are not included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08A, indicating that the information has been considered and made of record herein.

I certify that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application

#### CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. 1.10

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service for "Express Mail Post Office to Addressee" service, Express Mail Label No. EV426999744,in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

of Person Mailing Paper 5-Dec-06 Signature of Person Mailing Paper Date of Deposit

not more than three months prior to the filing of this Statement. A copy of the Japanese Search Report dated September 5, 2006 is enclosed.

It is respectfully noted that Applicant is submitting only those references cited in the Japanese Search Report that were not previously submitted with the Information Disclosure Statement filed on March 6, 2001.

In the event any fee is deemed necessary upon the filing of the attached Supplemental Information Disclosure Statement, the Commissioner is hereby authorized to charge any such fee which may be required during the pendency of this application to Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

> Respectfully submitted, AMYLIN PHARMACEUTICALS, INC.

Dated: 5-Dec-06

Registration No. 40,931

AMYLIN PHARMACEUTICALS, INC. 9360 Towne Centre Drive San Diego, CA 92121 Telephone: 858.552.2200

Facsimile: 858.552.1936

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

Complete if Known				
Application Number	09/719,410			
Filing Date	12-Dec-2000			
First Named Inventor	GOKE, Burkhard			
Art Unit	1654			
Examiner Name	Mohamed, Abdel A.			
Attorney Docket Number	0206-UTL-9			

	0.1	5 (1)	U. S. PATENT D	Name of Patentee or	Pages Columns Lines Where
Examiner C Initials* N	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
					Figures Appear
		US-			
		US-			
		US-			
······································		US-			
		US-	<del> </del>		
		US-			
		US-			
		US-			
	-	US-			
		US-	+		
	-	US-			
	_	US-			
	<del> </del>	US-			

		FOREI	<b>IGN PATENT DOCL</b>	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	<b>⊤</b> 6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	IVIVI-DD-1111		Of the leave the	
	1	WO 97/46584	12-11-1997	Boehringer Mannheim GMBH		
	1					
	<u> </u>					

Examiner Date Considered			
Examinor Constitution of the constitution of t	Evaminer	Date	· ·
	Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Art Unit (Use as many sheets as necessary) **Examiner Name** 

Attorney Docket Number

Sheet

2

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	BYRNE - GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subject with Impaired Glucose Tolerance; Diabetes; Volume 47; Abstract 0744, Page A192, (May-1998)	
	3	BYRNE - Human Studies with Glucagon-like-Peptide-1: Potential of the Gut Hormone for Clinical Use; Diabetes Medicine, Vol. 13; Issue 10; pages 854-860 (Oct-1996)	
<u> </u>			
	1		
Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for requiring this burden should be cost to the Chief Information Officer U.S. Potent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.